BioCentury | Nov 21, 2011
Company News

Medicis, Graceway deal

...in the U.S. and Canada. Graceway also markets MaxAir pirbuterol Autohaler to treat asthma and Estrasorb...
BioCentury | Jul 5, 2010
Finance

2H10 milestones

...multiforme (GBM) Submit regulatory application 2H10 Merck & Co. Inc. (NYSE:MRK)/Merck KGaA (Xetra:MRK) NOMAC/E2 nomegestrol acetate/estrogen estradiol...
BioCentury | Feb 25, 2008
Company News

Allergan, Graceway Pharmaceuticals Inc., Novavax deal

...Graceway acquired all assets related to the Estrasorb product line in North America from Novavax and...
...America from Novavax and Allergan for an undisclosed sum. Novavax retained the right to commercialize Estrasorb...
...elsewhere. Graceway granted Novavax a royalty-free license to micellar nanoparticle technology for applications unrelated to Estrasorb...
BioCentury | Oct 29, 2007
Company News

Allergan, Novavax deal

...The companies will end a 2005 deal under which NVAX manufactures and supplies Estrasorb to AGN...
...BioCentury, Oct. 24, 2005 & Oct. 22). NVAX plans to manufacture the remaining orders of Estrasorb...
...its Philadelphia manufacturing facility. NVAX said the move will reduce its cash burn and that Estrasorb...
BioCentury | Sep 24, 2007
Company News

Allergan, Esprit, Indevus deal

...for $370 million in cash. Esprit markets Sanctura trospium to treat overactive bladder (OAB) and Estrasorb...
...a once-daily formulation approved in August, from IDEV. Esprit has North American rights to Estrasorb...
BioCentury | Sep 24, 2007
Finance

Domain exits

...compounds targeting Hsp90 Esprit [being acq'd by Allergan] Markets overactive bladder drug Sanctura trospium and Estrasorb...
BioCentury | Sep 20, 2007
Company News

Allergan to acquire Esprit

...for $370 million in cash. Esprit markets Sanctura trospium to treat overactive bladder (OAB) and Estrasorb...
...a once-daily formulation approved in August, from Indevus (IDEV), and holds North American rights to Estrasorb...
BioCentury | May 28, 2007
Clinical News

NOMAC/E2: Completed Phase III enrollment

...Endocrine Molecular target: NA Description: Oral contraceptive with combination of nomegestrol acetate and the natural estrogen estradiol...
BioCentury | May 28, 2007
Clinical News

NOMAC/E2: Completed Phase III enrollment

...Endocrine Molecular target: NA Description: Oral contraceptive with combination of nomegestrol acetate and the natural estrogen estradiol...
BioCentury | May 22, 2006
Company News

Esprit, Novavax deal

...for milestones and royalties. Last year, Esprit received exclusive North American marketing rights to NVAX's Estrasorb...
Items per page:
1 - 10 of 69